Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
Peter Brodersen is a Professor at the Department of Biology, University of Copenhagen , specializing in Bioinformatics and RNA Biology . His research focuses on RNA modification (m6A), YTHDF proteins, and small RNA pathways in plants. Recent research trends from his group include: (1) molecular mechanisms of ARGONAUTE-small RNA interactions, (2) m6A-YTHDF regulatory systems in plant development, and (3) RNAi-independent roles of DICER-LIKE proteins in antiviral defense. Collaborations span Denmark and international institutions. Publications highlight cross-disciplinary work bridging computational biology and experimental plant genetics. Key subfields include RNA structure, epigenetic regulation, and antiviral immunity.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Ramesh Shanmughom Pillai is a Full Professor at the Department of Molecular Biology, University of Geneva, Switzerland. He holds additional roles as a Visiting Professor at the University of Kumamoto, Japan, and has been a Group Leader at EMBL Grenoble and a postdoctoral fellow at the Friedrich Miescher Institute. His research focuses on RNA modifications, epigenetics, and piRNA pathways in germline biology. Pillai has received prestigious awards including the ERC Consolidator Grant and The RNA Society Scaringe Award. Education: BSc Botany (University of Kerala, India) MSc Biotechnology (IIT Roorkee, India) PhD in Cell Biology (University of Bern, Switzerland) Research Interests: Pillai’s work centers on RNA biology, particularly the role of RNA modifications (e.g., m6A, m6Am) in development and fertility. He investigates piRNA biogenesis, transposon silencing, and the molecular mechanisms of RNA-protein interactions. His studies bridge biochemistry, genetics, and structural biology to elucidate how RNA molecules regulate critical biological processes. Teaching & Service: At the University of Geneva, he teaches Molecular Biology courses (BSc/MSc levels) and advises 5 PhD students and 4 postdocs. He chairs the ERC Consolidator Grant Review Panel and organizes major conferences like the PIWI/piRNAs Meeting and Swiss RNA Workshop. Pillai also serves on editorial boards for Nucleic Acids Research and RNA . Awards: ERC Consolidator Grant (2015) Best PhD Thesis Award (2003) RNA Society Scaringe Award (2005) Grants & Labs: Funded by ERC Starting and Consolidator Grants, his lab explores RNA modification networks in germ cells. Former trainees include Professors Simon Conn (Flinders University) and Hao Wu (CAS, China).
Claudio R. Alarcón is an Associate Professor in Pharmacology at Yale University School of Medicine. His research focuses on RNA metabolism's role in development, health, and disease, particularly RNA modifications and non-coding RNAs. He joined Yale in 2017 after postdoctoral training at The Rockefeller University and holds a PhD from Cornell University (2009) and a BSc from Pontificia Universidad Católica de Chile (1999). Research Interests: Functional roles of m6A RNA modifications MicroRNA biogenesis and cancer progression Non-coding RNA regulation in metastasis Key Appointments: Primary Faculty, Yale Cancer Biology Institute Member, Yale Cancer Center Faculty, Yale Combined Program in Biological and Biomedical Sciences His lab integrates bioinformatics, molecular, and cellular approaches to study cancer metastasis mechanisms, including miRNA processing disruptions and SOX4/TMEM2 pathways linked to clinical outcomes.
Brian D. Gregory is a Professor of Biology at the University of Pennsylvania's School of Arts & Sciences. His research focuses on RNA modifications, computational biology, and plant genetics, particularly studying how RNA modifications regulate gene expression in plants and animals. He holds a Ph.D. from Harvard University (2005) and a B.S.A. from the University of Arizona (2000). Research Interests: RNA epitranscriptomics (e.g., m6A, NAD+ caps) RNA secondary structure and protein interactions Genomic approaches to study plant stress responses Development of high-throughput sequencing tools like PIP-seq Recent Work Highlights: Recent studies include analyzing pathogen-induced RNA modifications' role in plant immunity (Plant Cell 2023), global RNA structure/protein interaction mapping, and epitranscriptomic dynamics in drought tolerance. His lab's work bridges computational methods with molecular genetics to uncover post-transcriptional regulatory mechanisms. Lab & Collaborations: The Gregory Lab uses Arabidopsis thaliana as a primary model organism but also explores animal systems. They collaborate with institutions like Cornell University and have developed protocols published in Current Protocols in Molecular Biology. Teaching: BIOL 4231: Genome Sciences and Genomic Medicine BIOL 6010: Communication for Biologists
Guillaume Chanfreau is a Professor in the Department of Chemistry and Biochemistry within the College of Letters and Science at the University of California Los Angeles (UCLA). His research focuses on fundamental mechanisms of RNA metabolism, with particular emphasis on RNA splicing, decay pathways, and ribonuclease functions. His work spans molecular biology, biochemistry, and genetics, utilizing yeast as a primary model organism to investigate conserved RNA processing mechanisms. Professor Chanfreau's research interests center on understanding how RNA processing pathways regulate gene expression. His work examines transcription termination, RNA splicing fidelity, RNA decay mechanisms, and the role of ribonucleases in cellular RNA homeostasis. He investigates how these processes are interconnected and how they respond to cellular stress conditions. His laboratory has made significant contributions to understanding how RNA quality control mechanisms prevent the accumulation of aberrant transcripts and maintain cellular health. Analysis of Chanfreau's recent publications (2020-2025) reveals a strong focus on RNA splicing mechanisms, RNA decay pathways, and ribonuclease functions. His work frequently employs yeast genetics combined with advanced RNA sequencing techniques. A notable trend is the increasing use of long-read sequencing technologies to analyze RNA isoforms and decay intermediates. His research consistently bridges fundamental molecular mechanisms with potential implications for understanding human diseases related to RNA processing defects. Professor Chanfreau has been continuously funded by the National Institutes of Health, with his current grant R35GM130370 (2019-2023) titled 'The Control of Gene Expression by Eukaryotic Ribonucleases' and previous long-term funding through R01GM061518 (2000-2019). His research program has supported numerous graduate students and postdoctoral researchers who have contributed to his extensive publication record spanning over two decades.
Dr. Ramanjulu Sunkar is a Regents Professor in the Department of Biochemistry & Molecular Biology at Oklahoma State University. He leads research on epigenetic and small RNA mechanisms in plant stress responses, focusing on gene regulation under drought, heat, and abiotic stresses. His work integrates genomic tools like ChIP, RNA sequencing, and CRISPR/Cas9 to study stress tolerance in crops. Education: B.Sc. (Sri Venkateswara University), M.Sc. and Ph.D. (Sri Krishnadevaraya University, India), followed by postdoctoral research at the Weizmann Institute (Israel), University of Bonn (Germany), and UC Riverside (USA). He joined Oklahoma State University in 2006, becoming Professor in 2016 and Regents Professor in 2024. Research Interests: Epigenetic modifications (DNA methylation, histone changes), microRNA-guided gene regulation, plant stress memory, and translational control mechanisms. His lab uses model systems like Arabidopsis, rice, and sorghum to study adaptive responses to environmental challenges. Grants: Over 15 grants, including USDA-funded projects on microRNA roles in photosynthesis, epigenetic control of drought tolerance, and systems genetics in rice. NSF-EPSCoR support for bioenergy research. Teaching: Courses include 'Plant Biochemistry,' 'Epigenetics,' and graduate supervision through research credits. Developed new courses on plant stress biology and molecular techniques. Labs/Teams: Leads a research group focused on epigenomics and RNA regulation in plants. Collaborates internationally on projects like the Arabidopsis transcriptome and stress memory mechanisms.
Dr. Sheng-Jian Ji is a Tenured Associate Professor at the School of Life Sciences, Department of Neuroscience at Southern University of Science and Technology (SUSTech) in Shenzhen, China. He also serves as the Academic Vice President of Shude Academy and was previously the first Deputy Director of Research and Graduate Affairs in the Department of Biology at SUSTech (2016-2018). As a leading neuroscientist specializing in RNA modification and neural development, Dr. Ji has established an internationally recognized research program. Dr. Ji's educational background includes: 2003-2007: Postdoctoral Fellow, Johns Hopkins University School of Medicine, Neurobiology 1998-2003: PhD in Biochemistry and Molecular Biology, Peking University School of Life Sciences 1994-1998: Bachelor's Degree in Biochemistry, Yantai University Department of Biochemistry Dr. Ji's research primarily focuses on developmental neurobiology, with particular emphasis on post-transcriptional regulation mechanisms including RNA modification and local translation of mRNA in axons. His laboratory is recognized as one of the leading international groups studying how mRNA modification (particularly m6A and m5C) regulates neural development and function. Through innovative approaches combining molecular biology, cell biology, and microfluidic technologies, his team has revealed important insights into axon growth, dendrite maintenance, cortical neurogenesis, and retinal development. His publication record shows a clear trajectory from fundamental mechanisms of RNA modification to applications in understanding neurological disorders and aging. Recent work has expanded into aging-related neural decline, cognitive functions, and potential therapeutic targets for neurological conditions. Dr. Ji has received numerous prestigious awards: 2020, 2016: SUSTech Excellent College Mentor 2020: SUSTech Biology Department Outstanding Service Award 2019: Guangdong Province Talent Youyue Card A 2017: Guangdong Provincial Professor of Neurobiology 2013: Jiangsu Distinguished Professor (Nanjing University) 2011: National Natural Science Award Second Prize (third contributor) As an educator, Dr. Ji teaches undergraduate Neurobiology and graduate Cellular and Molecular Neurobiology courses. He actively mentors students, with recent master's graduates including Yuan Jiaxin and Zhang Pingrui. His laboratory recruits postdoctoral fellows (with salaries of 335,000+ RMB annually), research assistants, and graduate students, providing comprehensive training in molecular techniques, neuronal cell culture, microfluidics, and omics approaches. Dr. Ji leads a vibrant research team that collaborates both within SUSTech and internationally. His work continues to advance understanding of RNA modification in neural development, function, and aging, with recent progress highlighted in June 2025.
Zhishan Wang, MD, PhD is a Research Professor in the Department of Pathology at Stony Brook University's Renaissance School of Medicine . His work focuses on environmental carcinogenesis , particularly mechanisms of cancer biology and cancer therapy , with a specialization in metal-induced carcinogenicity. Research Interests: Environmental Carcinogenesis Epigenetic and Epitranscriptomic Mechanisms Tumor Microenvironment Remodeling Metal Toxicity Pathobiology Non-Coding RNA Regulatory Networks Scientific Contributions: Analysis of 15 recent publications reveals expertise in: Metal-Induced Oncogenic Pathways (e.g., NF-κB activation, Hedgehog signaling) RNA Modification Dynamics (m6A, lncRNA-splicing interactions) Stem Cell Plasticity in Carcinogenesis Multi-Carcinogen Synergy Mechanisms Epigenetic-Genotoxic Interplay Transcriptomic Reprogramming by Toxicants
Silvia Monticelli is a Group Leader in Molecular Immunology at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland. She earned her Ph.D. from the University of Milan and has held research positions at San Raffaele Scientific Institute, King’s College London, and Harvard Medical School. Her research focuses on transcriptional and post-transcriptional regulation of immune responses, particularly in T lymphocytes and mast cells. Education: Ph.D. – University of Milan, Italy Postdoctoral training – San Raffaele Scientific Institute, Milan Research training – Randall Institute, King’s College London Research training – Center for Blood Research, Harvard Medical School Research Interests: Silvia Monticelli’s lab investigates the molecular mechanisms that control gene expression in immune cells. Her work spans epigenetic regulation , microRNA function , transcription factor networks , and RNA methylation in T cells and mast cells. A central theme is understanding how these mechanisms shape immune cell identity and function in health and disease. Publication Trends: Her recent publications (2020–2024) reflect a strong emphasis on RNA biology , epigenetic control , and immune regulation . She has contributed to high-impact journals such as Nature , Nature Immunology , and Science Advances , with work ranging from microRNA-mediated control of T cell activation to epigenetic regulation in mast cells and cancer immunity. Scientific Recognition: While no formal awards are listed, her work has been highlighted by editorial commentary and co-corresponding authorships in high-impact journals, indicating recognition within the immunology community. Labs & Affiliations: She leads a research group at the IRB in Bellinzona, focusing on immune cell regulation at the molecular level. Her lab is part of a broader European research network and collaborates with institutions like Harvard and the University of Milan.
Professor Yi Lyu is a faculty member at the Department of Hepatobiliary Surgery, College of Medicine, Xi’an Jiaotong University, with extensive leadership roles including Vice President of the university and Director of the First Affiliated Hospital. His research bridges hepatobiliary surgery, magnetic surgery, and biomedical engineering, focusing on innovative surgical devices and transplantation immunity. Bachelor's, Master’s, and Doctorate in Clinical Medicine and General Surgery from Xi’an Medical College Postdoctoral training in Surgery at Nippon Medical School Hospital, Tokyo His research interests span hepatobiliary surgery, magnetic surgery applications, cancer therapy, transplantation immunity, and biomedical engineering. Recent work emphasizes magnetic devices for vascular reconstruction during liver transplantation and immunomodulation via nanotherapeutics. Article trends reflect a strong focus on magnetic surgical technologies (6/15), cancer-related applications (4/15), and immune/gut microbiome interactions (3/15). High-impact publications (IF >15) include work on nanotherapeutics for muscle regeneration and catalytic systems in alkaline seawater. 2023 : Editor-in-Chief of Magnetic Medicine , National Key R&D Program grant (￥12M) 2022 : National Teaching Achievement Award, Annals of Surgery publications 2018 : Chinese Medical and Technology Award, NSFC Project grant 2015 : Ministry of Education Technology Invention Award
Yufei Huang is a Professor in the Department of Medicine at the University of Pittsburgh and the Leader of AI Research at UPMC Hillman Cancer Center. He holds a PhD and MS in Electrical Engineering from Stony Brook University. His work bridges artificial intelligence, bioinformatics, and cancer research, focusing on applications such as drug response prediction, epigenetic regulation, and viral pathogenesis. Huang is affiliated with both the School of Medicine and the School of Computing and Information, reflecting his interdisciplinary research. His contributions span computational tools for healthcare, including R Shiny apps for drug response analysis and machine learning models for unbiased patient representation. Research interests include AI-driven oncology, molecular mechanisms of cancer progression, and leveraging genomics for precision medicine. He has contributed to studies on lung cancer therapeutics, viral infections (e.g., SARS-CoV-2 and KSHV), and epigenetic modifications like m6A methylation. His lab develops innovative algorithms for single-cell transcriptomics and spatial biology to unravel disease mechanisms. Notable projects include MetGen, a generative model for metastatic cancer prediction, and m6A-express, which deciphers RNA methylation's role in gene expression. His work on CASTOR1 phosphorylation highlights biomarker discovery in lung adenocarcinoma. Huang's interdisciplinary approach integrates machine learning, virology, and computational biology to address critical challenges in healthcare and cancer research.
Jianjun Chen, Ph.D. serves as Professor and Chair of the Department of Systems Biology and Director of the Center for RNA Biology and Therapeutics at City of Hope's Beckman Research Institute. Appointed Chair in August 2020, he previously served as Professor and Vice Chair from 2017-2020. He also holds the Simms/Mann Family Foundation Chair in Systems Biology since 2018. Dr. Chen's research focuses on RNA and DNA epigenetic mechanisms in cancer development and therapy resistance. His laboratory has made seminal contributions to understanding RNA modifications including N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), and 7-methylguanosine (m⁷G), and their roles in cancer initiation, progression, drug resistance, and immune evasion. The lab also studies DNA epigenetic regulation through TET proteins and develops novel therapeutic strategies targeting epigenetic regulators. His recent publications reveal trends in RNA epigenetics, cancer metabolism, immune evasion mechanisms, and therapeutic targeting of epigenetic regulators. His work spans multiple cancer types including leukemia, lymphoma, and solid tumors, with emphasis on translating basic discoveries into clinical applications. Research Scholar of the American Cancer Society (2011) Scholar of The Leukemia & Lymphoma Society (2017) Researcher of the Year, The Pamela B. Katten Memorial Leukemia Research Foundation Award (2014) The Leukemia & Lymphoma Society Scholar CDP Achievement Award (2022) Fellow of the American Association for the Advancement of Science (AAAS) (2023) Dr. Chen's research program is supported by multiple R01 grants from the National Cancer Institute. His laboratory actively mentors researchers and has developed several small-molecule inhibitors with strong therapeutic potential in preclinical models. The Chen Laboratory is dedicated to translating fundamental discoveries in RNA and DNA epigenetics into effective clinical therapies for cancer patients. The laboratory operates within City of Hope's comprehensive cancer center, collaborating with clinical teams to bridge basic research and patient care. Current projects focus on developing prognostic systems for cancer risk stratification and creating targeted therapeutic strategies that inhibit aberrant epigenetic regulators such as FTO, IGF2BP2, YTHDF2, METTL16, and TET1.
